Gardasil on Trial: Questioning the Cervical Cancer Vaccine
Apr 14, 2025•10 min
Episode description
Story at-a-glance
- Gardasil's ability to prevent cervical cancer is being questioned, with experts citing a lack of long-term studies proving reduced cancer rates
- While Gardasil targets specific HPV strains, concerns exist that it allows for the emergence of other harmful strains, thus canceling the vaccine’s intended benefits
- Reports of severe side effects, including heart complications and even deaths, raise serious safety concerns, warranting caution
- The vaccine's aggressive marketing, despite the proven effectiveness of regular pap smears, suggests Gardasil's benefits have been exaggerated while risks have been downplayed
- Lawsuits alleging that Merck concealed risks and overstated Gardasil's efficacy are underway, casting doubt on the company's transparency and raising trust issues regarding pharmaceutical marketing